719 abstracts found.



Results filter

Tumour- and treatment-related colostomy rates following 5Fluorouracil (5FU) and Mitomycin (MMC) or 5FU and Cisplatin (Cisp) chemoradiation (CRT) with or without maintenance chemotherapy in squamous cell carcinoma of the anus: Results of the randomised phase III trial ACT II

Year:

Session type:

Rob Glynne-Jones1, Latha Kadalayil2, Helen Meadows2, David Cunningham3, Les Samuel4, Ian Geh5, Charles Lowdell6, Roger James7, Sandy Beare2, Rubina Begum2, Jonathan Ledermann2, David Sebag-Montefiore8
1Mount Vernon Centre for Cancer Treatment, Northwood, UK, 2Cancer Research UK & University College London Cancer Trials Centre, London, UK, 3Royal Marsden Hospital, London, UK, 4Aberdeen Royal Infirmary, Aberdeen, UK, 5Queen Elizabeth Hospital, Birmingham, UK, 6Imperial College Healthcare NHS Trust, London, UK, 7Tonbridge, UK, 8St James’s Institute of Oncology, Leeds, UK

Modafinil for fatigue in lung cancer: multicentre, randomised, double-blinded, placebo-controlled trial: effect, dose response and patient satisfaction

Year:

Session type:

Bee Wee1,4, Susan Dutton1, Kate Fife2, Fiona Blackhall3, Ronja Bahadori4, Rose Wharton1, Mary O'Brien5, Paddy Stone6, Tim Benepal6, Anna Spathis2
1University of Oxford, Oxford, UK, 2Addenbrookes Hospital, Cambridge, UK, 3Christie Hospital, Manchester, UK, 4Oxford University Hospitals NHS Trust, Oxford, UK, 5Royal Marsden Hospital, London, UK, 6St George's Hospital, London, UK

Results from the UNBIASED study (UK – Netherlands – Belgium International SEDation study) : reported practices of physicians and nurses in three European countries

Year:

Session type:

Jane Seymour1, Luc Deliens2, Judith Rietjens2,3, Sigrid Sterckx4, Jayne Brown5, Agnes van der Heide3
1University of Nottingham, Nottingham, UK, 2Vrije Universiteit, Brussels, Belgium, 3Erasmus MC, Rotterdam, The Netherlands, 4Ghent University, Ghent, Belgium, 5De Montfort University, Leicester, UK

Obesity and the outcome of young breast cancer patients in the UK: The POSH study

Year:

Session type:

Ellen Copson1, Ramsey Cutress1, Bryony Eccles1, Clarice Wong1, Tom Maishman1, Sue Gerty1, Louise Dent1, Douglas Altman2, Lorraine Durcan1, Peter Simmonds1, the POSH steering group and D.M. Eccles1
1Cancer Sciences Academic Unit and Clinical Trials Unit, Faculty of Medicine, University of Southampton, Southampton, UK, 2Centre for Statistics in Medicine, Oxford, Oxford, UK

Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme

Year:

Session type:

Amanda Dibden1, Judith Offman1, Dharmishta Parmar1, Jacquie Jenkins2, Jo Slater3, Kathie Binysh4, Joan McSorley5, Suzanne Scorfield6, Pam Cumming7, Xiao-Hui Liao8, Michael Ryan9, Diane Harker10, Guy Stevens11, Nicola Rogers12, Roger Blanks13, Sarah Sellars14, Julietta Patnick14, Stephen Duffy1
1Queen Mary, University of London, London, UK, 2East Midlands Quality Assurance Reference Centre, Nottingham, UK, 3East of England Quality Assurance Reference Centre, Cambridge, UK, 4London Quality Assurance Reference Centre, London, UK, 5Northern Ireland Quality Assurance Reference Centre, Belfast, UK, 6North East, Yorkshire and the Humber Quality Assurance Reference Centre, Newcastle Upon Tyne, UK, 7North West Quality Assurance Reference Centre, Oldham, UK, 8South Central Quality Assurance Reference Centre, Oxford, UK, 9South East Coast Quality Assurance Reference Centre, East Sussex, UK, 10South West Quality Assurance Reference Centre, Bristol, UK, 11Public Health Wales, Cardiff, UK, 12West Midlands Quality Assurance Reference Centre, Birmingham, UK, 13University of Oxford, Oxford, UK, 14NHS Cancer Screening Programmes, Sheffield, UK

NRP1 drives tip-cell selection downstream of Notch signaling by inhibiting ALK5 activation

Year:

Session type:

Irene Maria Aspalter1, Emma Gordon2, Anne Eichmann2, Holger Gerhardt1
1London Research Institute CRUK, London, UK, 2Yale School of Medicine, New Haven, USA

An all-Ireland population-based study of past and current physical and psychological side-effects following prostate cancer treatments

Year:

Session type:

Heather Kinnear1, Frances Drummond2, Linda Sharp2, Anna Gavin1Lesley Anderson1
1Queen's University Belfast, Belfast, UK, 2National Cancer Registry Ireland, Cork, Ireland

Tetraploidy is permissive for chromosomal instability and accelerates cancer genome evolution

Year:

Session type:

Sally Dewhurst1, Nicholas McGranahan1, Rebecca Burrell1, Andrew Rowan1, Eva Gronroos1, Charles Swanton1,2
1Cancer Research UK, London Research Institute, London, UK, 2University College London Cancer Institute, Huntley Street, London, UK

Clinical implications of a prostate cancer risk SNP profile in 2 treatment cohorts

Year:

Session type:

Chee Goh1, Edward Saunders1, Daniel Leongamornlert1, Tokhir Dadaev1, Malgorzata Tymrakiewicz1, Karen Thomas2, Elizabeth Selvadurai2, Ruth Woode-Amissah2, Nadiya Mahmud1, Elena Castro3, David Olmos3, Michelle Guy1, Koveela Govindasami1, Rosemary Wilkinson1, Emma Sawyer1, Ali Amin Al Olama4, Douglas Easton4, Zsofia Kote-Jarai1, Chris Parker1,2, Rosalind Eeles1,2
1The Institute of Cancer Research, London, UK, 2The Royal Marsden NHS Foundation Trust, London, UK, (CNIO) Spanish National Cancer Research Centre, 4The University of Cambridge, Cambridge, UK

AZ Student Prize winner: MicroRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer

Year:

Session type:

Nicola Valeri1, Chiara Braconi1, Pierluigi Gasparini2, Claudio Murgia3, Andrea Lampis1, Matteo Fassan7, Viola Paulus-Hock1, Jonathan Hart4, Sergei Grivennikov5, Francesca Lovat2, Giovanni Lanza6, Roberta Gafa'6, Gerard Nuovo2, Rachel Ridgway3, Wendy Frankel2, Joanna Groden2, Peter Vogt4, Owen Sansom3, Michael Karin5, Carlo Croce2
1Institute of Cancer Sciences, University of Glasgow, Glasgow, UK, 2The Ohio State University, Columbus, USA, 3Beatson Institute for Cancer Research, Glasgow, UK, 4The Scripps Research Institute, La Jolla, USA, 5University California at San Diego, San Diego, USA, 6University of Ferrara, Ferrara, Italy, 7ARC-NET Research Centre University of Verona, Verona, Italy

Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer

Year:

Session type:

David Church1,2, Enric Domingo1, Oliver Sieber3, Rajarajan Ramamoorthy1,4, Brian Davidson4, David Kerr2, Rachel Midgley2, Ian Tomlinson1
1The Wellcome Trust Centre for Human Genetics, Oxford, UK, 2Oxford Cancer Centre, University of Oxford, Oxford, UK, 3Ludwig Institute for Cancer Research, Melbourne, Australia, 4University College London, London, UK

miR-21 down-regulates Junctional Adhesion Molecule-A (JAM-A) during colorectal cancer progression

Year:

Session type:

Andrea Lampis1, Claudio Murgia2, Viola Paulus-Hock1, Matteo Fassan3, Joanne Edwards1, Paul Horgan1, Owen Sansom2, Michael Karin4, Carlo Croce5, Chiara Braconi1, Nicola Valeri1
1Institute of Cancer Sciences, University of Glasgow, Glasgow, UK, 2The Beatson Institute for Cancer Research, Glasgow, UK, 3ARC-NET Research Centre, University of Verona, Verona, Italy, 4University of California, San Diego, USA, 5The Ohio State University, Columbus, USA

Deep analysis of signalling plasticity in a breast cancer kinase network during acquisition of resistance to PI3K and mTORC1/2 inhibitors

Year:

Session type:

Edmund Wilkes1,2, Pedro Cutillas1,2
1Barts Cancer Institute, Queen Mary University of London, School of Medicine and dentistry, London, UK, 2MRC Clinical Sciences Centre, London, UK

Pan-genomic analysis of hypoxic breast cancer reveals lncRNAs associated with clinicopathological features

Year:

Session type:

Hani Choudhry1,2, Johannes Schödel3, Carme Camps2, Spyros Oikonomopoulos2, Peter Ratcliffe3, Adrian Harris4, Ioannis Ragoussis2, David Mole3
1Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia, 2The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, 3Henry Wellcome Building for Molecular Physiology, University of Oxford, Oxford, UK, 4Department of Oncology, John Radcliffe Hospital, University of Oxford, Oxford, UK

Volatile biomarkers discriminate between bronchial epithelial cells with distinct mutations

Year:

Session type:

Michael Davies1, Orna Barash2, Raneen Jeries2, Nir Peled3, Maya Ilouze3, Russell Hyde1, Michael Marcus1, Hossam Haick2, John Field1
1University of Liverpool, Liverpool, UK, 2Technion - Israel Institute of Technology, Haifa, Israel, 3Tel Aviv University, Tel Aviv, Israel

CCP Score: A novel genetic test for prostate cancer

Year:

Session type:

Dan Berney1, Michael Brawer2, Matthew Cooperberg3, Gregory Swanson4, Stephen Freedland5, Julia Reid2, Gabrielle Fisher1, Gerry Lanchbury2, Alexander Gutin2, Steven Stone2, Peter Carroll3, Jack Cuzick1
1Queen Mary University of London, London, UK, 2Myriad Genetic Laboratories, Salt Lake City, USA, 3University of California, San Francisco, USA, 4University of Texas Health Science Center at San Antonio, San Antonio, USA, 5Duke University Medical Center and Durham VA Medical Center, Durham, USA

BACR AZ Frank Rose Award: The signalling networks regulating cell shape

Year:

Session type:

Chris Bakal
The Institute of Cancer Research, London UK

The Hippo pathway polarises the actin cytoskeleton during collective migration of Drosophila border cells

Year:

Session type:

Ichha Khanal1, Eliana Lucas1, Pedro Gaspar1, Georgina Fletcher1, Cedric Polesello1, Nicolas Tapon1, Barry Thompson1
1Cancer Research UK London Research Institute, London, UK

Socio-economic patterning in early mortality of patients aged 0-49 years diagnosed with primary bone cancer in Great Britain, 1985-2008

Year:

Session type:

Theme:

Karen Blakey1, Richard Feltbower2, Roger Parslow2, Peter James1, Charles Stiller3, Paul Norman4, Craig Gerrand5, Richard McNally1
1Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK, 2Paediatric Epidemiology Group, University of Leeds, Leeds, UK, 3Childhood Cancer Research Group, Department of Paediatrics, University of Oxford, Oxford, UK, 4School of Geography, University of Leeds, Leeds, UK, 5(NICR) Northern Institute for Cancer Research

The Resistant Cancer Cell Line (RCCL) collection

Year:

Session type:

Theme:

Martin Michaelis1, Mark Wass1, Jindrich Cinatl2
1University of Kent, Canterbury, UK,2Goethe-University, Frankfurt am Main, Germany

IDENTIFYING EPIGENETIC CHANGES IN BREAST TUMOURS THAT METASTASISE TO THE BRAIN

Year:

Session type:

Theme:

Rajendra P Pangeni1, David Huen1, Katherine Ashton2, Carol Walker3, Timothy P Dawson2, Charles H G Davis2, Farida Latif4, John L Darling1, Tracy J Warr1, Mark R Morris1
1Research Institute in Healthcare Science, University of Wolverhampton, Wolverhampton, UK,2Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK,3The Walton Centre NHS Foundation Trust, Liverpool, UK,4Department of Medical and Molecular Genetics, University of Birmingham, Birmingham, UK

Porfimer sodium photodynamic therapy (PDT) plus stenting versus stenting alone in patients (pts) with advanced or metastatic cholangiocarcinomas and other biliary tract tumours (BTC): a randomised phase lll study (Photostent-02)

Year:

Session type:

S P Pereira1,S K Hughes5,M Roughton5,P O'Donoghue3,H Wasan2,J Valle4,J Bridgewater6
1University College London, The Institute of Hepatology, London, United Kingdom,2Imperial College Healthcare Trust, London, United Kingdom,3University College London Hospital, London, United Kingdom,4Christie Hospital NHS Foundation Trust, University of Manchester, Manchester, United Kingdom,5University College London & Cancer Research UK Cancer, London, United Kingdom,6University College London, Cancer Institute, London, United Kingdom

Thirty-day post-operative mortality after colorectal cancer surgery in England

Year:

Session type:

Eva Morris1,Faye Taylor1,James Thomas1,Phil Quirke1,Paul Finan1,Michel Coleman2,Bernard Rachet2,David Forman1
1University of Leeds, Leeds, United Kingdom,2London School of Hygiene and Tropical Medicine, London, United Kingdom

Clinical development of catumaxomab (Removab) in malignant ascites

Year:

Session type:

Simon Parsons1,Rolf Linke2,Mirko Essing2
1Nottingham City Hospital, Nottingham, United Kingdom,2Fresenius Biotech GmbH, Munich, Germany

Capecitabine/oxaliplatin vs 5FU/oxaliplatin combination chemotherapy in advanced colorectal cancer (aCRC): the MRC COIN trial experience

Year:

Session type:

Ayman Madi1,Richard Wilson2,Richard Adams3,Matt Seymour4,Angela Meade5,Jim Cassidy6,David Fisher5,Sarah Kenny5,Rick Kaplan5,Tim Maughan3
1Freeman Hospital, Newcastle upon Tyne, United Kingdom,2Belfast City Hospital, Belfast, United Kingdom,3Velindre Hospital, Cardiff, United Kingdom,4St James's University Hospital, Leeds, United Kingdom,5Medical Research Council, London, United Kingdom,6The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Mismatch repair status in stage II colorectal cancer : Substantially reduced recurrence rate in mismatch repair deficient tumours supports routine testing

Year:

Session type:

Gordon Hutchins1,Katie Southward1,Kelly Handley2,Laura Macgill2,Claire Beaumont1,Jens Stalhschmidt3,Susan Richman1,Matt Seymour4,David Kerr5,Richard Gray2,Phil Quirke1
1Leeds Institute of Molecular Medicine, Leeds, United Kingdom,2Birmingham Clinical Trials Unit, Birmingham, United Kingdom,3Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom,4Cancer Research UK Cancer Centre, Leeds, United Kingdom,5Sidra Medical and Research Centre, Doha, Qatar

A novel colorectal cancer susceptibility SNP in the EIF3H promoter influences patient survival and response to treatment

Year:

Session type:

Christopher Smith1,David Fisher2,Rebecca Harris1,Timothy Maughan3,Shelley Idziaszczyk1,Valentina Moskvina4,James Colley1,Angela Meade2,Cleo Bonnet1,Hannah West1,Richard Kaplan2,The COIN Collaborative Group5,The COIN-B Collaborative Group6,Jeremy Cheadle1
1Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom,2MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, United Kingdom,3Department of Oncology and Palliative Care, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom,4Biostatistics and Bioinfomatics Unit, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom,5The COIN Trial steering group and collaborators, -, United Kingdom,6The COIN-B Trial steering group and collaborators, -, United Kingdom

Integrated analysis of genome-wide copy number and expression changes reveals novel genes in oesophageal adenocarcinoma

Year:

Session type:

Xin Yi Goh1,Jonathan Rees1,Anna Paterson1,Suet-Feung Chin2,Maria O'Donovan3,Derek Alderson4,Bauke YIstra5,Carlos Caldas2,Rebecca Fitzgerald1
1Hutchison-MRC Research Centre, Cambridge, United Kingdom,2Cancer Research-UK Cambridge Research Institute, Cambridge, United Kingdom,3Department of Pathology, Addenbrooke’s Hospitals NHS Trust, Cambridge, United Kingdom,4Academic Department of Surgery, Queen Elizabeth Hospital, Birmingham, United Kingdom,5Department of Pathology, VU University Medical Center, Amsterdam, Netherlands

Comparison of Loss of MLH1 and MSH2 Expression Between Oesophageal Cancer and Other Sporadic Cancers of the Gastrointestinal Tract – Relationship With Survival in 1027 Cases

Year:

Session type:

Imran Inam1,Karen Maude2,Lindsay Ward1,Jacinta Murray1,Susan Richman1,Wolfram Mueller3,Abeezar Sarela2,Henry Sue-Ling2,Peter Howdle2,Philip Quirke1,Heike Grabsch1
1Department of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Leeds, West Yorkshire, United Kingdom,2Medicine Surgery and Anaesthesia, Leeds Institute of Molecular Medicine, Leeds, West Yorkshire, United States,3Gemeinschaftspraxis Pathologie, Starnberg, Germany

Discovery of novel Pin1 inhibitors by structure-guided fragment evolution that downregulate cyclin D1 expression in PC-3 prostate cancer cells

Year:

Session type:

Jonathan Moore1,Andrew Potter1,Stuart Ray1,Victoria Oldfield1,Claire Nunns1,Christophe Fromont1,Christopher Northfield1,Louisa Gueritz1,Christopher Bryant1,Simon Scrace1,David Robinson1,Natalia Matassova1,Lisa Baker1,Allan Surgenor1,Pawel Dokurno1,Ben Davis1,Christine Richardson1,James Murray1
1Vernalis, Cambridge, United Kingdom

BACR Translational Research Award: Molecular taxonomy of breast cancer: is there a gold standard?

Year:

Session type:

Britta Weigelt1,Alan Mackay2,Roger A’hern3,Rachael Natrajan2,David SP Tan2,Mitch Dowsett2(4),Mitch Dowsett2(4),Mitch Dowsett2(4)

1

Cancer Research UK London Research Institute, UK,2The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK,3
,Cancer Research UK Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, UK,4
,Academic Department of Biochemistry, Royal Marsden Hospital, London, UK


What reasons do patients give for declining or participating in early phase cancer trials?

Year:

Session type:

Susan Catt1,Carolyn Langridge1,Valerie Jenkins1,Denis Talbot2,Lesley Fallowfield1
1CRUK Psychosocial Oncology Group, Brighton & Sussex Medical School, Brighton, United Kingdom,2Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom

Physical Activity Intervention in Cancer Survivors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Year:

Session type:

Judy Ho1,Bryant Hui1,Daniel Fong2,Duncan Macfarlane3,Antoinette Lee4,Sharron Leung2,Ester Cerin3,Wynnie Chan1,Ivy Leung5,Sharon Lam6,Aliki Taylor7,KK Cheng8
1Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong,2Department of Nursing Studies, The University of Hong Kong, Hong Kong, Hong Kong,3Institute of Human Performance, The University of Hong Kong, Hong Kong, Hong Kong,4Department of Psychiatry, The University of Hong Kong, Hong Kong, Hong Kong,5Queen Elizabeth Hospital, Kowloon, Hong Kong,6Baptist University, Kowloon, Hong Kong,7Agmen Limited, Uxbridge, United Kingdom,8Dept of Public Health and Epidemiology, University of Birmingham, Birmingham, United Kingdom

The prognosis in palliative care study (PiPS)

Year:

Session type:

Bridget Gwilliam1,Matthew Gittens2,Chris Roberts2,Chris Todd2,Vaughan Keeley3,Stephen Barclay4,Laura Kelly5,Patrick Stone1
1St Georges's, University of London, London, United Kingdom,2University of Manchester, Manchester, United Kingdom,3Derby Hospitals Foundation Trust, Derby, United Kingdom,4University of Cambridge, Cambridge, United Kingdom,5East Surrey Hospital, Redhill, United Kingdom

Which research priorities are defined by young people with cancer- second consultation by the National Cancer Research Institute’s Teenage and Young Adult Core Consumer Group

Year:

Session type:

Lorna Fern1,James Ashton4,Katie Brooman4,Tom Grew4,Carol Irving2,Hannah Millington4,Carol Starkey4,David Wright3,Jeremy Whelan1
1University College Hospitals, London, United Kingdom,2Leeds Teaching Hospitals NHS Trusts, Leeds, United Kingdom,3Clatterbridge Centre for Oncology NHS Foundation Trust, Liverpool, United Kingdom,4NCRI Teenage & Young Adult Core Consumer Group, London, United Kingdom

Functional characterization of SET8 in prostate cancer cell lines

Year:

Session type:

Dhuha Alkharaif1,Kelly Armstrong1,Craig Robson1
1Newcastle University, Newcastle Upon Tyne, United Kingdom

Cancer death data as part of the National End of Life Care Intelligence Network Website 

Year:

Session type:

Andy Pring1,Kate Ruth1,Matthew Iles1,Luke Hounsome1,Veronique Poirier1,Julia Verne1
1South West Public Health Observatory, Bristol, United Kingdom

Targeted intra-operative radiotherapy (TARGIT) for early stage breast cancer: the TARGIT-A trial at 10 years maximum follow up.

Year:

Session type:

Jayant Vaidya1,Jeffrey Tobias1,Mohammed Keshtgar1,David Joseph2,Frederik Wenz3,Max Bulsara4,Christobel Saunders2,Norman Williams1,Michael Baum1
1UCL, London, United Kingdom,2Sir Charles Gairdner Hospital, Perth, Australia,3Universitätsmedizin Mannheim, Mannheim, Germany,4University of Notre Dame, Fremantle, Australia

Survival after first course of palliative radiotherapy: An observational cohort study

Year:

Session type:

Matt Williams1,David Woolf1,Rob Hughes1,Jane Maher1,Jeanette Dickson1
1Mount Vernon Cancer Centre, London, United Kingdom

Functional evaluation of homologous recombination pathway in epithelial ovarian cancer and the potential for targeted chemotherapy with PARP inhibitors

Year:

Session type:

Asima Mukhopadhyay1,Sandra Soohoo1,Bisha Uzir1,Ahmed Elattar1,Sarah Wilkinson1,Aiste Cerbinskaite1,Nicola Curtin1,Richard Edmondson2
1Northern Institute for Cancer Research, Newcastle university, United Kingdom,2Northern Gynaecological Oncology Centre, Gateshead, United Kingdom

Four-fold increase in recruitment of cancer patients to NCRN portfolio studies between 2001 and 2010: a tale of investment bringing returns. 

Year:

Session type:

David Cameron2,Matt Cooper1,Bob Haward1,Rick Kaplan1,Karen Poole1,Nancy Lester3,Ruth McLaren1,Rachel Moser1,Mahesh Parmar1,Rachel Moser1,Maxine Stead3,Peter Selby3
1NIHR NCRN Co-ordinating centre, Leeds University, LEEDS, United Kingdom,2Universtiy of Edinburgh, EDINBURGH, United Kingdom,3NIHR CRN Co-ordinating Centre, Leeds University, LEEDS, United Kingdom,4MRC Clinical Trials Unit, LONDON, United Kingdom

MGMT methylation is strongly associated with and may precede IDH1/IDH2 mutations in adult astrocytic and oligodendroglial tumours

Year:

Session type:

Shani Mulholland1,Deborah S Malley1,Rifat Hamoudi1,Sylvia Kocialkowski1,Danita Pearson1,V.Peter Collins1,Koichi Ichimura1
1Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom

The primary health and supportive care needs of long-term cancer survivors

Year:

Session type:

Sian Harrison1,Eila Watson2,Nada Khan1,Alison Ward1,Monica Roche3,David Forman4,Peter Rose1
1Oxford University, Oxford, United Kingdom,2Oxford Brookes University, Oxford, United Kingdom,3Oxford Cancer Intelligence Unit, Oxford, United Kingdom,4Northern and Yorkshire Cancer Registry and Information Service, Leeds, United Kingdom

Discovery of New Pathways and Mechanisms of Notch Signalling in Angiogenesis

Year:

Session type:

Esther Bridges1,Anassuya Ramachandran1,Jie Zuo1,Tessa Peterkin1,Martin Taylor2,Harukazu Suzuki3,Philip Pinheiro1,Ji-Liang Li1,Roger Patient1,Adrian Harris1
1Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom,2Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom,3RIKEN Omics Science Center, Yokohama Institute, Yokohama, Japan

Targeting Notch in Pancreatic Cancer

Year:

Session type:

Natalie Cook1,Kris Frese1,Mike Jacobetz1,Meredith Caldwell-Jacobetz1,Tashinga Bapiro1,Aimee Michael2,Christopher Winter2,Duncan Jodrell1,David Tuveson1
1Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom,2Merck Research Laboratories, Boston, United States

Integration of miRNA and mRNA expression profiles in breast cancer identifies miRNA associated pathways and prognostic markers

Year:

Session type:

Francesca M. Buffa1,Carme Camps2,Laura Winchester2,Harriet Gee1,Helen Sheldon1,Marian Taylor1,Adrian L. Harris1,Jiannis Ragoussis2
1The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom,2The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

Chemo- and radio-sensitisation of hepatocellular carcinoma by the DNA-dependent protein kinase inhibitor NU7441

Year:

Session type:

Joanne Munck1,Liam Cornell1,Febrina Budhisetiawan1,David Newell1,Julia Bardos2,Helen Reeves1,Nicola Curtin1
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom,2KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom

Evaluation of a novel Ataxia telangiectasia mutated (ATM) and Rad3-related (ATR) inhibitor, NU6027

Year:

Session type:

Gary Beale1,Amy Peasland1,Lan Wang1,Emily Rowling1,Adam Hopkins1,William Cliby2,Jann Sarkaria2,Richard Edmondson1,Nicola Curtin1
1Newcastle University, Newcastle Upon Tyne, Tyne and Wear, United Kingdom,2Mayo Clinic, Rochester, Minnesota, United States

Induction of a tumor-promoting phenotype in human macrophages by necrotic debris: role of TLR4 and p38 MAP kinase.

Year:

Session type:

Russell Hughes1,Subhra Biswas2,Mary Woodall-Jappe3,Claire Lewis1
1Academic Unit of Inflammation and Tumour Targeting, Sheffield, S. Yorkshire, United Kingdom,2Singapore Immunology Network, Singapore, Singapore,3Eisai Inc, Andover, MA, United States

ACP McElwain Prize: P-Rex1 is a central component of metastasis in malignant melanoma

Year:

Session type:

Colin Lindsay1,Samuel Lawn1,William Faller1,Andrew Campbell1,Channing Der2,Kate Pedone2,Heidi Welch3,Lionel LaRue4,Iain Jackson5,Friedrich Beerman6,Brad Ozanne1,Owen Sansom1
1The Beatson Institute for Cancer Research, Glasgow, UK,2The University of North Carolina, Chapel Hill, USA,3The Babraham Institute, Cambridge, UK,4Centre de Recherche, Institut Curie, Paris, France,55MRC Human Genetics Unit, Edinburgh, UK,6ISREC, Epalinges, Switzerland